Total Payments
$105,216
2024 Payments
$1,523
Companies
9
Transactions
128
Medicare Patients
1,857
Medicare Billing
$77,990
Payment Breakdown by Category
Consulting$41,949 (39.9%)
Other$40,656 (38.6%)
Travel$18,270 (17.4%)
Food & Beverage$3,148 (3.0%)
Research$1,162 (1.1%)
Education$31.55 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $41,949 | 19 | 39.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,656 | 17 | 38.6% |
| Travel and Lodging | $18,270 | 40 | 17.4% |
| Food and Beverage | $3,148 | 46 | 3.0% |
| Unspecified | $1,162 | 4 | 1.1% |
| Education | $31.55 | 2 | 0.0% |
Payments by Type
General
$104,054
124 transactions
Research
$1,162
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Radius Health, Inc. | $41,769 | 64 | $0 (2023) |
| Shire North American Group Inc | $34,341 | 35 | $0 (2019) |
| Ascendis Pharma Inc | $21,957 | 15 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,903 | 4 | $0 (2024) |
| Chugai Pharmaceutical Co., Ltd. | $931.11 | 4 | $0 (2020) |
| Vertex Pharmaceuticals Incorporated | $930.00 | 2 | $0 (2022) |
| Amgen Inc. | $174.64 | 2 | $0 (2023) |
| Ultragenyx Pharmaceutical Inc. | $107.84 | 1 | $0 (2019) |
| Lilly USA, LLC | $102.03 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,523 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($1,523) |
| 2023 | $20,371 | 17 | Ascendis Pharma Inc ($19,077) |
| 2022 | $4,972 | 7 | Ascendis Pharma, Inc. ($2,880) |
| 2021 | $3,710 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($2,210) |
| 2020 | $3,975 | 8 | Radius Health, Inc. ($3,043) |
| 2019 | $18,308 | 23 | Shire North American Group Inc ($11,251) |
| 2018 | $32,918 | 52 | Radius Health, Inc. ($27,166) |
| 2017 | $19,440 | 17 | Shire North American Group Inc ($17,338) |
All Payment Transactions
128 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | Consulting Fee | Cash or cash equivalent | $1,522.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/07/2023 | Ascendis Pharma Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,310.00 | General |
| 07/07/2023 | Ascendis Pharma Inc | — | Travel and Lodging | Cash or cash equivalent | $50.00 | General |
| 06/16/2023 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $103.97 | General |
| 04/24/2023 | Ascendis Pharma Inc | — | Consulting Fee | Cash or cash equivalent | $1,239.00 | General |
| 04/07/2023 | Ascendis Pharma Inc | — | Consulting Fee | Cash or cash equivalent | $1,770.00 | General |
| 03/10/2023 | Ascendis Pharma Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,204.00 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Travel and Lodging | Cash or cash equivalent | $398.00 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Travel and Lodging | Cash or cash equivalent | $355.00 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Travel and Lodging | Cash or cash equivalent | $314.07 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $150.91 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $114.32 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $48.24 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $46.15 | General |
| 02/25/2023 | Ascendis Pharma Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $27.69 | General |
| 01/19/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/15/2023 | Radius Health, Inc. | Tymlos (Drug) | Education | In-kind items and services | $19.69 | General |
| Category: Endocrinology | ||||||
| 07/22/2022 | Radius Health, Inc. | Tymlos (Biological) | — | In-kind items and services | $186.88 | Research |
| Study: The Safety and Efficacy of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial • Category: Endocrinology | ||||||
| 06/16/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $472.50 | General |
| 04/27/2022 | Radius Health, Inc. | Tymlos (Biological) | — | In-kind items and services | $342.81 | Research |
| Study: The Safety and Efficacy of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial • Category: Endocrinology | ||||||
| 04/13/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $457.50 | General |
| 03/30/2022 | Radius Health, Inc. | Tymlos (Biological) | — | In-kind items and services | $236.25 | Research |
| Study: Efficacy and Safety of Abaloparatide in Men with Osteoporosis • Category: Endocrinology | ||||||
| 03/15/2022 | Radius Health, Inc. | Tymlos (Biological) | — | In-kind items and services | $395.63 | Research |
| Study: The Safety and Efficacy of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial • Category: Endocrinology | ||||||
| 02/05/2022 | Ascendis Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The Safety and Efficacy of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial | Radius Health, Inc. | $925.32 | 3 |
| Efficacy and Safety of Abaloparatide in Men with Osteoporosis | Radius Health, Inc. | $236.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 4 | 203 | 205 | $50,921 | $5,145 |
| 2021 | 6 | 958 | 980 | $262,643 | $32,625 |
| 2020 | 8 | 696 | 2,007 | $280,837 | $40,220 |
Total Patients
1,857
Total Services
3,192
Medicare Billing
$77,990
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 46 | 46 | $12,926 | $1,879 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 31 | 32 | $12,654 | $1,355 | 10.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 26 | 27 | $6,156 | $867.49 | 14.1% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2022 | 81 | 81 | $15,309 | $839.16 | 5.5% |
| 77081 | Dxa bone density measurement of forearm, finger, hand, or foot | Facility | 2022 | 19 | 19 | $3,876 | $204.06 | 5.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 154 | 166 | $74,151 | $12,384 | 16.7% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 162 | 162 | $44,519 | $6,674 | 15.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 113 | 121 | $28,808 | $6,382 | 22.2% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Facility | 2021 | 374 | 374 | $69,321 | $3,893 | 5.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 15 | $8,938 | $1,547 | 17.3% |
| 77081 | Bone density measurement of the core or extremities (e.g., radius, wrist, heel) | Facility | 2021 | 99 | 100 | $20,048 | $1,078 | 5.4% |
| 77085 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine), including assessment of vertebral fracture | Facility | 2021 | 41 | 42 | $16,858 | $665.28 | 3.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 20 | 1,320 | $92,700 | $20,280 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 142 | 146 | $49,758 | $8,421 | 16.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 59 | 62 | $38,409 | $5,144 | 13.4% |
| 77080 | Bone density measurement using dedicated x-ray machine | Facility | 2020 | 314 | 314 | $56,476 | $3,364 | 6.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 16 | $4,776 | $1,069 | 22.4% |
| 77085 | Bone density measurement using dedicated x-ray machine | Facility | 2020 | 54 | 54 | $21,042 | $860.26 | 4.1% |
| 77081 | Bone density measurement using dedicated x-ray machine | Facility | 2020 | 72 | 72 | $13,976 | $800.16 | 5.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 20 | 23 | $3,700 | $281.65 | 7.6% |
About Tamara Vokes
Tamara Vokes is a Endocrinology, Diabetes & Metabolism healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841353364.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tamara Vokes has received a total of $105,216 in payments from pharmaceutical and medical device companies, with $1,523 received in 2024. These payments were reported across 128 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($41,949).
As a Medicare-enrolled provider, Vokes has provided services to 1,857 Medicare beneficiaries, totaling 3,192 services with total Medicare billing of $77,990. Data is available for 3 years (2020–2022), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Chicago, IL
- Active Since 12/18/2006
- Last Updated 03/30/2022
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1841353364
Products in Payments
- Tymlos (Biological) $37,388
- NATPARA (Drug) $21,120
- NATPARA (PARATHYROID HORMONE) (Drug) $16,154
- Non-Covered Product (Drug) $931.11
- CRYSVITA (Drug) $107.84
- FORTEO (Drug) $102.03
- EVENITY (Biological) $70.67
- Tymlos (Drug) $19.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Chicago
Wahid Kassar, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.3M
Endocrinology, Diabetes & Metabolism $1.3M
David Oyer, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $272,437
Endocrinology, Diabetes & Metabolism $272,437
Aaron Benjamin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $228,391
Endocrinology, Diabetes & Metabolism $228,391
Dr. Grazia Aleppo, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $179,656
Endocrinology, Diabetes & Metabolism $179,656
Silvana Pannain
Endocrinology, Diabetes & Metabolism — Payments: $176,625
Endocrinology, Diabetes & Metabolism $176,625
Mark Molitch, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $105,398
Endocrinology, Diabetes & Metabolism $105,398